Related Experiment Video

Updated: Jun 20, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory drugs - can we combine all three?

A Hayes1

  • 1Oncology Unit Centre for Small Animal Studies, Animal Health Trust, Suffolk, UK. alison.hayes@aht.org.uk

Veterinary and Comparative Oncology
|September 17, 2009
PubMed

Insights

Cyclo-oxygenase (COX) inhibiting drugs offer potential benefits for treating canine and feline cancers by targeting specific molecular pathways. However, their effectiveness is limited as COX is only one of many aberrant pathways involved in cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Veterinary Medicine

Background:

  • Understanding cancer's molecular biology is key to developing targeted therapies.
  • Aberrant cell signaling pathways, like cyclo-oxygenase (COX), are implicated in cancer growth.
  • COX pathways are a focus in human and veterinary cancer research.

Purpose of the Study:

  • To explore the benefits and limitations of using COX-inhibiting drugs for cancer treatment in veterinary practice.
  • To evaluate COX inhibitors as a targeted therapy for animal cancers.

Main Methods:

  • Review of current scientific literature on COX pathways in cancer.
  • Analysis of the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in veterinary oncology.
  • Examination of aberrant cell signaling in carcinogenesis.

Main Results:

  • COX pathways are readily inhibited by commonly used NSAIDs in veterinary medicine.
  • COX inhibition presents a seemingly logical therapeutic target.
  • COX is one among numerous aberrant signaling pathways driving cancer.

Conclusions:

  • COX-inhibiting drugs show potential for veterinary cancer treatment but have limitations.
  • Targeted therapies must consider the complexity of multiple aberrant pathways in cancer.
  • Further research is needed to optimize COX inhibitor use in veterinary oncology.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...